Upstream Bio (NASDAQ:UPB) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.76) by 3.95 percent. This is a 1.35 percent increase over losses of $(0.74) per share from the same period last year. The company reported quarterly sales of $773.000 thousand which beat the analyst consensus estimate of $430.714 thousand by 79.47 percent. This is a 17.50 percent decrease over sales of $937.000 thousand the same period last year.